Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
Matthias PinterRakesh K JainPublished in: Science translational medicine (2018)
Renin-angiotensin system (RAS) inhibitors (RASi)-widely prescribed for the treatment of cardiovascular diseases-have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.
Keyphrases
- papillary thyroid
- cardiovascular disease
- squamous cell
- small cell lung cancer
- squamous cell carcinoma
- palliative care
- lymph node metastasis
- wild type
- electronic health record
- childhood cancer
- coronary artery disease
- metabolic syndrome
- young adults
- big data
- drug delivery
- deep learning
- smoking cessation
- human health
- climate change